Proactive Investors - Run By Investors For Investors

Regeneus: Access latest PPT from Proactive's CEO Sessions

John Martin discussed regenerative medicine with investors.
Regeneus: Access latest PPT from Proactive's CEO Sessions
John Martin, chief executive officer, Regeneus

Regeneus (ASX:RGS) chief executive officer, John Martin, joined Proactive's CEO Sessions in Sydney on Wednesday 14th June and Melbourne on Thursday 15th June.

The company provides exposure to the rapid growth global regenerative medicine market, utlising its world-calss stem cell and immuno-oncology technology platforms.

Its technology has been validated by positive pre-clinical and clinical data, and by a collaboration with a leading biopharma manufacturer in Japan.


View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use